Author

Mark Holton

Broad Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

Arvind RaviiD· 2 shared Daniel M Ferrer· 2 shared Gad A. GetziD· 2 shared Guillaume UrtechoiD· 2 shared Aaron Timothy GriffiniD· 1 shared Alexander Richter· 1 shared Alice Tsang ShawiD· 1 shared Andrea CalifanoiD· 1 shared

Activity by Year

2022-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Arvind RaviORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Culturomics-Guided Precision FMT Enables Stable Antibiotic-Independent Engraftment via Metabolic Niche Targeting

Daniel M Ferrer, Mark Holton, Minshen Yang, Ileana Villamil, Guillaume Urtecho

This paper develops a culturomics-guided FMT framework that enables stable, antibiotic-independent engraftment by targeting metabolic niches in recipient microbiomes.

bioRxiv · Oct 26, 2026 · PreprintMicrobiology

Metagenome-scale Modeling to Assess Microbiome Metabolic Complementarity for Precision Microbiota Transplantation Therapies

Zetian Zhang, Mark Holton, Daniel M Ferrer, Arielle D. Tripp, Alexander Richter, Purushottam D. Dixit, Guillaume Urtecho

This paper develops a metagenome-scale metabolic model to predict FMT outcomes by assessing donor-recipient metabolic compatibility in IBS patients.

Gut Microbes · Sep 2, 2026Peer-reviewedMicrobiology

Single Cell RNA-sequencing of BCG naive and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM mediated immune-suppressive pathway

Ivan Jurić, Emily E. Fink, Hong Qiu, P. Desprez, Arvind Ravi, Mark Holton, Vladimir Makarov, Nima Almassi, Booki Min, Gad A. Getz, Timothy An-thy Chan, Tyler Joseph Alban, Angela H. Ting, Byron Lee

This study uses single-cell RNA sequencing to identify a CD6/ALCAM-mediated immune-suppressive pathway in recurrent NMIBC, suggesting CD6 as a potential therapeutic target.

npj Precision Oncology · Sep 26, 2025Peer-reviewedCancer Biology

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

Arvind Ravi, Justin F. Gainor, Monica B. Arniella, Mark Holton, Samuel S. Freeman, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron Timothy Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira A. Rizvi, Biagio Ricciuti, , Matthew David Hellmann

This study identifies molecular and immune features associated with response to anti-PD-(L)1 therapy in NSCLC using a cohort of 393 patients.

bioRxiv · Mar 21, 2022 · PreprintGenomics